Compounded GLP-1 Medications: What They Are and How They Are Regulated

What Are Compounded GLP-1 Medications?

Compounded GLP-1 medications are preparations of glucagon-like peptide-1 (GLP-1) receptor agonists — such as semaglutide, tirzepatide, or liraglutide — that are mixed or formulated by a licensed compounding pharmacy under a physician's prescription for an individual patient, rather than manufactured by a pharmaceutical company under FDA approval.

GLP-1 receptor agonists work by mimicking a naturally occurring hormone your body releases after eating. They activate GLP-1 receptors in the pancreas, gut, and brain, which can reduce appetite, slow gastric emptying, improve blood glucose regulation, and support weight reduction in appropriate patients (Wilding et al., 2021, New England Journal of Medicine). FDA-approved GLP-1 medications — including Ozempic®, Wegovy®, Mounjaro®, and Zepbound® — have undergone extensive clinical trials demonstrating their safety and efficacy before reaching patients.

Compounded versions of these same active ingredients emerged at scale during the nationwide drug shortages of 2022–2024, when manufacturer supply could not keep pace with surging patient demand. What makes compounded preparations different — and why the regulatory picture has changed significantly — is what this guide explains in detail. 

How Compounding Pharmacies Work: 503A vs. 503B

Understanding compounded GLP-1 medications requires understanding the two legal frameworks that govern pharmacy compounding in the United States. These frameworks are governed by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and confusing them is one of the most common errors in patient-facing reporting on this topic.

Section 503A: Traditional Patient-Specific Compounding

A 503A pharmacy is a state-licensed compounding pharmacy that prepares customized medications for individual patients based on a valid prescription from a licensed prescriber. These pharmacies are primarily regulated by state boards of pharmacy, with limited FDA oversight. They may only compound a medication that is "essentially a copy" of a commercially available drug under narrow, patient-specific exceptions — for instance, when a patient has a documented allergy to an inactive ingredient in the branded product, or requires a dose strength that is not commercially available.

Routine compounding of semaglutide or tirzepatide by 503A pharmacies — simply because a patient prefers a lower-cost alternative — is not a legally valid basis under the FD&C Act. Patient preference and cost savings alone are insufficient justifications (U.S. Food & Drug Administration, 2025).

Section 503B: Outsourcing Facilities

A 503B outsourcing facility is a larger-scale compounder that is registered with the FDA and may produce compounded drugs in bulk for distribution to healthcare providers and facilities, with or without individual patient prescriptions. These facilities must comply with Current Good Manufacturing Practices (cGMP), the same manufacturing standards applied to conventional drug manufacturers. However, the drugs they produce are still not FDA-approved, meaning they have not undergone the FDA's pre-market review for safety, effectiveness, or quality.

The critical distinction: 503B facilities are subject to FDA oversight for manufacturing standards, but their drug products themselves are not reviewed or approved by the FDA before reaching patients.

Why Compounded GLP-1s Became So Widely Available

To understand the current regulatory environment, it helps to understand how compounded GLP-1s became mainstream.

Semaglutide was placed on the FDA's official drug shortage list in 2022 due to overwhelming demand following Wegovy's approval for chronic weight management. Tirzepatide was added to the shortage list in December 2022, shortly after Mounjaro's approval. Under the FD&C Act, a shortage designation creates a legal pathway for both 503A and 503B compounders to produce "essentially copy" versions of the drug — temporarily lifting the usual restrictions.

What followed was rapid market growth. Compounded GLP-1 preparations — typically priced between 300 per month compared to brand-name costs exceeding $1,000 per month — became widely available through telehealth platforms and online pharmacies (Pharmacy Times, 2026). At the peak of the shortage era, compounded versions are estimated to have accounted for approximately 30% of total U.S. GLP-1 supply (onhealthcare.tech, 2026). That legal window has now closed.

The FDA's 2025–2026 Regulatory Changes: What Has Actually Changed

The regulatory landscape for compounded GLP-1 medications has shifted decisively since late 2024. Patients and clinicians navigating this space need accurate, current information — not an outdated description of the shortage-era rules.

Shortage Resolutions

The FDA declared the tirzepatide injection shortage resolved in December 2024. The semaglutide injection shortage was declared resolved in February 2025. Both determinations triggered the statutory end of the shortage-based compounding pathway (FDA, 2025).

With the shortage designations removed, the primary legal basis for mass-scale compounding of these drugs — both by 503A pharmacies and 503B outsourcing facilities — was eliminated. The FDA established phased enforcement deadlines: for 503A semaglutide compounders, enforcement discretion ended April 22, 2025; for 503B semaglutide outsourcing facilities, the deadline was May 22, 2025.

FDA's April 2026 Proposed Rule: The 503B Bulks List

On April 30, 2026, the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the regulatory mechanism that governs which active pharmaceutical ingredients (APIs) outsourcing facilities may use in bulk compounding. In its announcement, the FDA stated it found "no clinical need" for outsourcing facilities to compound these three substances from bulk drug substances (FDA, 2026).

This proposal, if finalized, would close the last remaining legal pathway for large-scale bulk compounding of these GLP-1 agents by 503B facilities — even in the event of a future shortage designation. A public comment period was open through June 29, 2026 (Federal Register, 2026).

Legal Challenges

The Outsourcing Facilities Association filed federal lawsuits challenging both the tirzepatide and semaglutide shortage resolutions. Courts denied preliminary injunctions in both cases, allowing the enforcement deadlines to stand (Pharmacy Times, 2026). As of the date of this article, the regulatory direction is clear: the broad market for compounded GLP-1 medications that characterized 2022–2024 no longer has a legal foundation.

What Remains Permissible Under 503A

The April 2026 proposal does not directly alter the 503A framework. Patient-specific compounding by licensed 503A pharmacies may still be legally permissible in narrow circumstances where:

•  A patient has a documented allergy to a specific inactive ingredient in the FDA-approved branded product
•  A dose strength or concentration not commercially available is clinically required
•  A prescriber documents individualized, patient-specific medical necessity — not a formulaic or generalized rationale

Patient preference, insurance non-coverage, and cost savings are explicitly insufficient legal bases for 503A compounding of these medications (Orrick, 2026).

Safety Considerations: What the Data Shows

Regulatory changes aside, a clear picture of the clinical safety profile of compounded GLP-1 preparations has emerged from post-market surveillance data.

As of April 2025, the FDA had received over 520 adverse event reports related to compounded semaglutide and more than 480 reports associated with compounded tirzepatide, some of which required hospitalization (American Medical Women's Association, 2025; University of Illinois Chicago Drug Information Group, 2025). The true number of adverse events is likely higher, as state-licensed 503A pharmacies are not required to submit adverse event data to the FDA.

 A peer-reviewed pharmacovigilance analysis published in Expert Opinion on Drug Safety (2025) examined FDA Adverse Event Reporting System (FAERS) data from 2018 through 2024. The study found that compounded GLP-1 receptor agonists were associated with statistically higher reporting odds ratios for abdominal pain (ROR 2.84), diarrhea (ROR 1.59), nausea (ROR 1.27), cholecystitis (ROR 3.39), and suicidality (ROR 6.34) compared to non-compounded formulations. Reporting odds ratios for prescribing and preparation errors were also higher for compounded products (Ramirez et al., Expert Opinion on Drug Safety, 2025).

 Many reported adverse events involved dosing errors. Compounded GLP-1s are typically dispensed as multi-dose vials rather than pre-filled auto-injector pens, and some patients measured doses in units based on insulin syringes rather than in milligrams or milliliters. This created a setting where some patients administered 5 to 20 times their intended dose due to unfamiliarity with syringe measurement (University of Illinois Chicago Drug Information Group, 2025).

 Additional concerns the FDA has identified include:

 ● Variability in drug concentration between and within compounders

● Use of unapproved salt forms of semaglutide whose safety and efficacy are unknown

● Counterfeit products entering the market through online channels

● Compounders falsely marketing their preparations as "generic" versions of FDA-approved drugs

 In September 2025, the FDA issued more than 50 warning letters to GLP-1 compounders and manufacturers for making false or misleading claims — including suggestions that their compounded products are generic equivalents or carry the same safety and efficacy profile as the FDA-approved drugs (Wilson Sonsini, 2025).

How Compounded GLP-1s Differ From FDA-Approved Medications

This distinction is foundational and often misrepresented.

Compounded semaglutide and tirzepatide are not FDA-approved finished products and are not therapeutically interchangeable with Ozempic®, Wegovy®, Mounjaro®, or Zepbound®.

What Patients Currently on Compounded GLP-1s Should Know

If you have been receiving compounded semaglutide, tirzepatide, or liraglutide through a telehealth platform or compounding pharmacy, several realities apply as of July 2026:

Do not stop your medication abruptly without speaking to your prescribing physician. Discontinuation of GLP-1 therapy without medical guidance may affect blood glucose management in patients with type 2 diabetes and may be associated with weight regain. Your provider can assess your individual clinical situation and guide transition options.

Your provider's legal authority to prescribe a compounded GLP-1 has narrowed significantly. A valid compounded prescription now requires patient-specific, documented medical necessity — not simply a preference for a lower-cost alternative. If your provider cannot document a clinically justified reason your medical needs cannot be met by the FDA-approved product, the compounded prescription may no longer be on firm legal ground.

FDA-approved alternatives may be more accessible than they were in 2022–2024. Semaglutide and tirzepatide shortages have been resolved. Manufacturer savings programs, patient assistance programs, and prior authorization pathways through insurance may help reduce the cost of brand-name GLP-1 medications. Ask your provider or pharmacist about available options specific to your situation.

Be cautious of online providers continuing to offer compounded GLP-1s without individualized clinical review. The regulatory environment now requires patient-specific documentation. Providers offering compounded GLP-1s without careful clinical review of your specific circumstances may not be operating within current legal parameters.

Questions to Ask Before Starting Any GLP-1 Program

Whether you are considering an FDA-approved or compounded GLP-1 medication, the following questions help identify a trustworthy clinical program:

About the prescribing process:

•  Is a licensed U.S. physician reviewing my complete health history before issuing a prescription?
•  What clinical criteria determine whether I am an appropriate candidate?
•  Who do I contact if I experience side effects or have concerns about my medication?

About the medication itself:

•  Is this an FDA-approved product or a compounded preparation?
•  If compounded, what is the documented clinical justification specific to my case?
•  Where is the pharmacy licensed, and what quality standards does it follow?

About ongoing care:

•  Will I receive regular clinical check-ins, not just an initial consultation?
•  What is the plan if the medication is not effective or causes adverse effects?

A legitimate, clinically supervised program answers all of these questions clearly and does not pressure patients to proceed before they are comfortable with the answers.

Who Should Not Use GLP-1 Medications

GLP-1 receptor agonists — whether FDA-approved or compounded — are not appropriate for all patients. Patients should not use these medications if they have:

•  A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
•  A history of pancreatitis (FDA prescribing information for semaglutide and tirzepatide)
•  Known hypersensitivity to the active ingredient or any components of the formulation
•  Current pregnancy or breastfeeding — GLP-1 receptor agonists should be discontinued prior to planned pregnancy; discuss timing with your physician
•  Severe gastroparesis or other significant gastrointestinal motility disorders
•  End-stage renal disease (certain GLP-1 agents) — consult your prescriber

This list represents general contraindication categories. Only a licensed physician reviewing your complete health history can determine whether a GLP-1 medication may be appropriate for you.

Frequently Asked Questions

Are compounded GLP-1 medications legal in 2026?

The legal status of compounded GLP-1 medications narrowed significantly in 2025–2026. The FDA shortage-based compounding pathway closed when semaglutide and tirzepatide were removed from the FDA shortage list in early 2025. Large-scale bulk compounding by 503B outsourcing facilities is no longer legally permissible under the current regulatory environment. Patient-specific compounding by 503A pharmacies may remain permissible in narrow circumstances — specifically when a prescriber can document individualized clinical necessity that cannot be met by the FDA-approved product — but patient preference and cost are not sufficient justifications.

How is a compounded GLP-1 different from a generic GLP-1?

They are fundamentally different. A generic drug is an exact copy of an FDA-approved medication that has undergone FDA review for bioequivalence, safety, and quality. Generic drugs cannot be marketed until the brand-name drug's patent expires. Compounded GLP-1 preparations are not generics, have not been reviewed by the FDA for equivalence to brand-name products, and are not therapeutically interchangeable with FDA-approved drugs. Some compounders have falsely described their products as generics — the FDA issued warning letters to more than 50 such companies in September 2025 for this misleading practice.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide is not the same as Ozempic® or Wegovy®, and is not therapeutically interchangeable with these products. The FDA does not review compounded preparations for safety, efficacy, or quality before patients receive them. Formulation differences — including inactive ingredients, concentration, salt forms, and delivery method — may affect how the drug behaves in the body. Some compounders have used salt forms of semaglutide (such as semaglutide acetate or sodium) that are not components of any FDA-approved drug product and whose safety profile is unknown.

What happened to compounded tirzepatide?

The FDA declared the tirzepatide shortage resolved in December 2024. This triggered the end of the shortage-based compounding pathway. Enforcement deadlines for 503B outsourcing facilities compounding tirzepatide ran until March 19, 2025. Legal challenges by the Outsourcing Facilities Association were unsuccessful — courts denied preliminary injunctions in both the tirzepatide and semaglutide cases. The FDA's April 2026 proposal to exclude tirzepatide from the 503B Bulks List, if finalized, would close the last remaining pathway for large-scale bulk compounding.

Why are there still online providers offering compounded GLP-1s?

The legal landscape has changed but enforcement is not instantaneous, and some narrow legal exceptions still exist for 503A patient-specific compounding. Some providers are operating under the 503A framework with appropriate patient-specific clinical documentation. Others may be operating outside current legal parameters. Patients should ask their provider to explain the specific legal and clinical basis for any compounded GLP-1 prescription in 2026.

What are the safety risks of compounded GLP-1 medications specifically?

Beyond the standard side effects common to all GLP-1 receptor agonists — including nausea, vomiting, diarrhea, and constipation — compounded preparations carry additional specific risks. A 2025 pharmacovigilance study in Expert Opinion on Drug Safety found compounded GLP-1 RAs were associated with higher reporting rates for abdominal pain, diarrhea, nausea, cholecystitis, and suicidality compared to non-compounded formulations. Dosing errors are a significant documented risk, particularly with multi-dose vials requiring patient self-measurement. Purity, concentration, and sterility may vary between compounding pharmacies.

Can I transition from a compounded GLP-1 to an FDA-approved version?

Many patients may be able to transition to FDA-approved semaglutide or tirzepatide. Both drugs are currently commercially available without shortage status. Your prescribing physician should guide any transition, including dosing adjustments to account for potential differences in formulation. Insurance coverage, patient savings programs, and manufacturer assistance programs may help reduce the cost. Ask your provider what options are available for your specific situation.

What should I do if I experience side effects from a compounded GLP-1?

Contact your prescribing provider promptly. If you experience severe symptoms — including severe abdominal pain, signs of pancreatitis (persistent severe pain radiating to your back), signs of an allergic reaction, or significant changes in vision — seek emergency medical care. Adverse events associated with compounded medications can also be reported to the FDA via MedWatch at fda.gov/safety/medwatch.

References

American Medical Women's Association. (2025). Physician practice alert: Compounded GLP-1 drugs face imminent legal deadlines. https://amwa-doc.org/physician-practice-alert-compounded-glp-1-drugs-face-imminent-legal-deadlines/

Federal Register. (2026, May 1). List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act (Docket No. 2026-08552). https://www.federalregister.gov/documents/2026/05/01/2026-08552

Orrick, Herrington & Sutcliffe LLP. (2026, May 1). FDA moves to shut the door on large-scale compounding of GLP-1 drugs. https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs

Pharmacy Times. (2026, July). FDA moves to permanently close the door on compounded GLP-1s. https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s

Ramirez, A., et al. (2025). Safety analysis of compounded GLP-1 receptor agonists: A pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety, 25(3), 581–588. https://doi.org/10.1080/14740338.2025.2499670

U.S. Food and Drug Administration. (2025). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

U.S. Food and Drug Administration. (2026, April 30). FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

University of Illinois Chicago Drug Information Group. (2025, August). What are the safety concerns regarding compounded GLP-1 receptor agonists? https://dig.pharmacy.uic.edu/faqs/2025-2/august-2025-faqs/what-are-the-safety-concerns-regarding-compounded-glp-1-receptor-agonists/

Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Wilson Sonsini Goodrich & Rosati. (2025, October). FDA sends warning letters to more than 50 GLP-1 compounders and manufacturers. https://www.wsgr.com/en/insights/fda-sends-warning-letters-to-more-than-50-glp-1-compounders-and-manufacturers.html